UNITED STATES (VOP TODAY NEWS) — The results of the first clinical trials of the new anti-glomerular blast vaccine showed its high effectiveness in curbing tumor growth.
Thomas Jefferson University scientists tested IGV-001, a vaccine against brain cancer in the United States, on 33 patients diagnosed with a thyroid cancer.
According to the researchers, “the vaccine slowed growth of the tumor and prolong the patient’s life several months,” and it is important not to detect side effects.
The basis of the vaccine is cancerous cells taken from a patient during surgery to remove the tumor, according to a statement released by the researchers. These cells are treated with special substances, and then injected into the body again.
The researchers used two different doses of these cells in the first phase tests, and found that when the larger dose was used, tumor growth stopped and the patient lived 21.9 months. While patients who received traditional treatment lived 14.6 months.
The researchers say they observed the condition of some patients after the vaccine was used for a period of 39 months.
The second phase of clinical trials for this effective vaccine is scheduled to begin in the final months of this year.
This article is written and prepared by our foreign editors writing for VOP from different countries around the world – edited and published by VOP staff in our newsroom.
Support The VOP from as little as $1 – it only takes a minute. Thank you.
We are the Voice of People — the only funding and support we get from people – we are categorically not funded by any political party, any government somewhere or from any grouping that supports certain interests – the only support that makes VOP possible came from you.
VOP Today News — Breaking news source, real-time coverage of the world’s events, life, politics, business, finance, economy, markets, war and conflict zones.
Contact us: firstname.lastname@example.org